PMCB
PharmaCyte Biotech Inc (PMCB)
Healthcare • NASDAQ • $0.76-5.53%
- Symbol
- PMCB
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.76
- Daily Change
- -5.53%
- Market Cap
- $8.11M
- Trailing P/E
- N/A
- Forward P/E
- -1.99
- 52W High
- $1.51
- 52W Low
- $0.63
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.46
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to Pha…
Company websiteResearch PMCB on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.